These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Treatment of metastatic uveal melanoma: review and recommendations. Albert DM; Niffenegger AS; Willson JK Surv Ophthalmol; 1992; 36(6):429-38. PubMed ID: 1589858 [TBL] [Abstract][Full Text] [Related]
10. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Daud A; Kluger HM; Kurzrock R; Schimmoller F; Weitzman AL; Samuel TA; Moussa AH; Gordon MS; Shapiro GI Br J Cancer; 2017 Feb; 116(4):432-440. PubMed ID: 28103611 [TBL] [Abstract][Full Text] [Related]
11. A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma. Minor DR; Kim KB; Tong RT; Wu MC; Kashani-Sabet M; Orloff M; Eschelman DJ; Gonsalves CF; Adamo RD; Anne PR; Luke JJ; Char D; Sato T Cancer Biother Radiopharm; 2022 Feb; 37(1):11-16. PubMed ID: 35021863 [No Abstract] [Full Text] [Related]
13. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Chandran SS; Somerville RPT; Yang JC; Sherry RM; Klebanoff CA; Goff SL; Wunderlich JR; Danforth DN; Zlott D; Paria BC; Sabesan AC; Srivastava AK; Xi L; Pham TH; Raffeld M; White DE; Toomey MA; Rosenberg SA; Kammula US Lancet Oncol; 2017 Jun; 18(6):792-802. PubMed ID: 28395880 [TBL] [Abstract][Full Text] [Related]
14. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. Klemen ND; Wang M; Rubinstein JC; Olino K; Clune J; Ariyan S; Cha C; Weiss SA; Kluger HM; Sznol M J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32209601 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies. Komatsubara KM; Carvajal RD Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938 [TBL] [Abstract][Full Text] [Related]
16. Targeted therapy for uveal melanoma. Triozzi PL; Eng C; Singh AD Cancer Treat Rev; 2008 May; 34(3):247-58. PubMed ID: 18226859 [TBL] [Abstract][Full Text] [Related]
17. Treatment of uveal melanoma: where are we now? Yang J; Manson DK; Marr BP; Carvajal RD Ther Adv Med Oncol; 2018; 10():1758834018757175. PubMed ID: 29497459 [TBL] [Abstract][Full Text] [Related]
18. Radiation and systemic immunotherapy for metastatic uveal melanoma: a clinical retrospective review. Tran DH; Shanley R; Giubellino A; Tang PH; Koozekanani DD; Yuan J; Dusenbery K; Domingo-Musibay E Front Oncol; 2024; 14():1406872. PubMed ID: 39026970 [TBL] [Abstract][Full Text] [Related]
19. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma. Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663 [TBL] [Abstract][Full Text] [Related]
20. Treatment of metastatic uveal melanoma in 2022: improved treatment regimens and improved prognosis. Reichstein D; Brock A; Lietman C; McKean M Curr Opin Ophthalmol; 2022 Nov; 33(6):585-590. PubMed ID: 36094043 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]